Double-blind Comparative Study of SYR-472
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Akita
-
Akita-shi, Akita, Japan
-
-
Chiba
-
Matsudo-shi, Chiba, Japan
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan
-
-
Hiroshima
-
Fukuyama-shi, Hiroshima, Japan
-
-
Hokkaido
-
Ishikari-shi, Hokkaido, Japan
-
Nakagawa-gun, Hokkaido, Japan
-
Sapporo-shi, Hokkaido, Japan
-
-
Ibaragi
-
Naka-shi, Ibaragi, Japan
-
-
Kanagawa
-
Sagamihara-shi, Kanagawa, Japan
-
-
Kumamoto
-
Kumamoto-shi, Kumamoto, Japan
-
-
Osaka
-
Kashiwara-shi, Osaka, Japan
-
Osaka-shi, Osaka, Japan
-
Suita-shi, Osaka, Japan
-
-
Tokyo
-
Arakawa-ku, Tokyo, Japan
-
Bunkyo-ku, Tokyo, Japan
-
Chiyoda-ku, Tokyo, Japan
-
Chuo-ku, Tokyo, Japan
-
Itabashi-ku, Tokyo, Japan
-
Katsushika-ku, Tokyo, Japan
-
Mitaka-shi, Tokyo, Japan
-
Shinjuku-ku, Tokyo, Japan
-
-
Yamaguchi
-
Shunan-shi, Yamaguchi, Japan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The participant is an outpatient.
- The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Exclusion Criteria:
- The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.(e.g., subjects who require hospitalization or subjects who were hospitalized within 24 weeks prior to the commencement of the observation period)
- The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
|
|
Experimental: SYR-472 100 mg
|
|
|
Active Comparator: Alogliptin 25 mg
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycosylated hemoglobin (HbA1c)
Time Frame: 24 weeks.
|
Measurement of change in HbA1c (ratio of hemoglobin bound to glucose).
|
24 weeks.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Medical Director, Takeda (Note: This product was divested to Teijin Pharma Limited in 2023)
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SYR-472/CCT-002
- U1111-1128-6104 (Registry Identifier: WHO)
- JapicCTI-121839 (Registry Identifier: JapicCTI)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.